Six hundred and twenty-four centers from 43 countries reported a total of 31 322 hematopoietic SCT (HSCT) to this 2009 European Group for Blood and Marrow Transplantation (EBMT) survey with 28 033 first transplants (41% allogeneic, 59% autologous). The main indications were leukemias (31%; 92% allogeneic), lymphomas (58%; 12% allogeneic), solid tumors (5%; 6% allogeneic) and non-malignant disorders (6%; 88% allogeneic). There were more unrelated than HLAidentical sibling donors (51 vs 43%) for allogeneic HSCT; the proportion of peripheral blood as stem cell source was 99% for autologous and 71% for allogeneic HSCT. Allogeneic and autologous HSCT continued to increase by about 1000 HSCT per year since 2004. Patterns of increase were distinct and different. In a trend analysis, allogeneic HSCT increased in all World Bank Categories (P ¼ 0.01, two sided; all categories), autologous HSCT increased in middle-(P ¼ 0.01, two sided) and low-income (P ¼ 0.01, two sided) countries. EBMT practice guidelines appeared to have an impact on trend, with a clear increase in absolute numbers within the categories 'standard' and 'clinical option' for both allogeneic and autologous HSCT (P ¼ 0.01, two sided; for both allogeneic and autologous HSCT) and a clear decrease in autologous HSCT for the 'developmental' and 'generally not recommended' indications (P ¼ 0.01, two sided). These data illustrate the status and trends of HST in Europe.
Introduction
Hematopoietic SCT (HSCT) has become an established procedure for many congenital and acquired disorders of the hematopoietic system worldwide. 1, 2 The first survey of the Worldwide Network for Blood and Marrow Transplantation reflects this situation by its report of more than 50 000 such procedures for the year 2006. 3 Forecasts predict an ongoing increase in the near future. 4, 5 This fits with the information from the past series of the annual surveys of the European Group for Blood and Marrow Transplantation (EBMT). 6 These data show how the activity surveys have become an important instrument to describe the status of hematopoietic SCT in Europe, to observe trends and to monitor changes in technology use. [7] [8] [9] [10] [11] They capture the numbers of HSCT in the preceding year from each participating team by indication, donor type and stem cell source. Their standardized structure over many years and the excellent commitment by the participating teams allows now to observe changes over time and to evaluate factors associated with such changes. 11 More recently, the survey has included information on cellular transplants with hematopoietic stem cells for non-hematopoietic use as well as for the use of non-hematopoietic stem and progenitor cells. 10 This coincides with the recent interest of the World Health Organization (www.who.org) in cell and tissue transplants and further stresses the need for adequate and timely information. 12 All EBMT analyses in previous years have shown an increase in absolute HSCT numbers and in transplant rates of about 5-10% for allogeneic and of 3-5% for autologous HSCT following the earlier findings of a high predictability of transplant rates. 6, 9 The recent Worldwide Network for Blood and Marrow Transplantation survey showed significant differences in use and availabilities of HSCT between the different global regions. 3 It identified availability of resources, governmental support and access of patients to the transplant as key factors for transplant rates. 3 We were therefore interested to evaluate more closely this increase of HSCT within EBMT and changes in HSCT application. Specifically, we wanted to know whether the increase in the most recent years was similar for all indications and in all countries or whether the increase was more owing to a catching up of those countries Definitions Transplant numbers. Transplant numbers in the survey reflect numbers of patients with a first HSCT; this includes patients with a planned tandem transplant. Additional transplants include: re-transplants (autologous or allogeneic), defined as unplanned HSCT for rejection or relapse after a previous HSCT; and multiple transplants, defined as subsequent transplants within a planned double or triple autologous or allogeneic transplant protocol. Information on stem cell source includes BM, peripheral blood or cord blood; transplants with more than one source were categorized as cord blood HSCT if cord blood was present or peripheral blood HSCT if only BM and peripheral blood were present. Information on numbers of non-myeloablative conditioning transplants, as defined by EBMT (http://www.ebmt.org/4Registry/registry6.html), was collected generically and not for individual transplants.
Information on additional cellular therapies was subdivided into donor lymphocyte infusions, mesenchymal stromal cell therapies, HSCT for non-hematopoietic use or non-hematopoietic stem cell therapies. Collection of information was harmonized with identical surveys by EULAR (European League against Rheumatism; www.eular.org) and TERMIS-EU (Tissue Engineering and Regenerative Medicine International Society; www.termis.org).
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The basic classification from the EBMT report on current practice 14 was used to separate indications into standard, optional, developmental and generally not indicated, with minor modifications (see Supplementary Table 1) .
Transplant rates. Transplant rates, defined as numbers of HSCT per 10 million inhabitants, were computed for each country, without adjustments for patients who crossed borders and received their HSCT in a foreign country. Population numbers were obtained from the US census office database (www.census.gov). Countries were grouped into high-income (4US$11 906 GNI per capita), middleincome (US$3856-11 905 GNI per capita) and low-income (USo$3855 GNI per capita) countries as previously reported by the World Bank Definitions and their GNI/ capita (www.worldbank.org) 6 and as listed in the Appendix.
Statistical analysis
Multiple regression analyses assessed trends over time for the period from 2004 to 2009, with focus on increase or decrease of HSCT numbers, HSCT rates and growth rates for all transplants, and allogenic and autologous HSCT separately. World Bank Category assessed the respective values for changes concerning countries, and EBMT practice guidelines for disease indications. Two-sided comparisons were used in comparisons.
Results

Participating teams
Of the 624 teams, 378 (61%) did both allogeneic and autologous transplants; 224 (36%) teams restricted their activity to autologous transplants and nine teams ( 
Numbers of HSCT in 2009
Stem cell source and donor type in 2009
There were clear differences in the use of stem cell source between autologous and allogeneic HSCT (Figure 2 ). Of the 16 591 autologous first transplants, 142 (1%) were BM derived and 16 449 (99%) were derived from PBSCs or from combined peripheral blood and BM. There were two autologous HSCT reported with cord blood cells, one for a child with neuroblastoma and one, gene modified, for a child with an inherited disease of metabolism ( Figure 2a , Table 1 ). Of the 11 442 allogeneic first transplants, 2569 (22%) were BM, 8119 (71%) were peripheral blood and 754 (7%) were cord blood transplants (Figure 2b ). The choice of stem cell source differed by main indication for all types of allogeneic HSCT. BM remained the preferred source of stem cells for allogeneic transplants for nonmalignant disorders (51%) (Figure 2c) , with an even higher proportion of BM for HLA-identical sibling donor transplants (59%). In contrast, peripheral blood was the preferred choice for malignant disorders, with the highest proportion of peripheral blood for leukemias (73%) (Figure 2d ; Table 1 ).
Donors for the 11 442 allogeneic HSCT were HLAidentical siblings (4856 BM or peripheral blood donors; 42 and 46% targeted cord blood HSCT; 0.4%), an other family member (637; 6%), an unrelated BM or peripheral blood donor (5167; 45%) or an unrelated cord blood donor (701; 6%) ( Figure 3 ).
Use of reduced-intensity conditioning in 2009
Numbers of non-myeloablative HSCT continued to increase from 4397 in 2008 to 4842 in 2009 at the same rate as allogeneic HSCT. Non-myeloablative conditioning was used for 39% of all allogeneic HSCT, a similar number to that of last year's survey.
Donor lymphocyte infusions
There were 1936 patients reported as having received donor lymphocyte infusions in 2009; this corresponds to 16% of all patients with an allogeneic HSCT and to about 40% of reported patients with reduced-intensity conditioning HSCT.
Additional cellular therapies 105 teams in 22 countries reported to the cellular therapy survey in 2009. The 1142 cellular therapies other than conventional HSCT included 520 (46%) mesenchymal stem cell therapies, 304 (27%) hematopoietic stem cell therapies and 318 (28%) 'other source' stem cell therapies for non-hematopoietic use or non-hematopoietic cellular therapies. The majority of the MSC therapies (59%) were allogeneic; the majority of the cellular therapies for non-hematopoietic use were autologous (70%). Indications for the 1142 cellular therapies were cardiovascular (416, 36%; 64% autologous), neurological (34, 3%; 50% autologous), tissue repair (192, 17%, 98% autologous), epithelial (90, 8%; 73% autologous), auto immune disease (103, 9%; 84% autologous) and unspecified (307, 27%; 7% autologous).
Detailed information on cell source was provided for 814, 215 (26%) allogeneic, 599 (74%) autologous procedures. There were 264 therapies performed using HSC (32%), 232 using MSC (29%), 82 using chondrocytes (10%), 51 using keratinocytes (6%), 50 using dermal fibroblasts (6%) and 135 using an unspecified cell source (2%).
Transplant rates
Transplant rates differed substantially between participating countries (Figure 4 ). These differences relate to all types of HSCT. Total transplant rates in Europe ranged from 0 HSCT per 10 million inhabitants in several countries to 758 in Italy (943 in Israel) (median: 311). Transplant rates for allogeneic HSCT ranged from 0 (several countries) to 312 in Germany (508 in Israel) (median: 88). They ranged from 0 (several countries) to 497 in Italy (436 in Israel) (median: 210) for autologous HSCT. (Table 1) . Increase or decrease in HSCT differed depending on disease indication and main donor type. Increase in allogeneic HSCT was highest in absolute numbers for AML and highest in relative proportion for lymphoproliferative disorders, CLL and myelodysplastic syndrome. A decrease in allogeneic HSCT (À52%) was only observed, as reported previously, for CML. Numbers of allogeneic HSCT for solid tumors remained low over the whole observation period. In contrast, autologous HSCT increased above the average of þ 12% in total for lymphoproliferative disorders ( þ 24%), but decreased for all other indications, including leukemias (À52%). A clear exception, although with still small absolute numbers, forms the indication of autoimmune disorders (increase by 146%). There were substantial differences by World Bank Category (Figures 5a and b) . Countries in the high-income category showed a clear increase in absolute numbers of allogeneic HSCT (P ¼ 0.01, two sided), with a slight decrease in its growth rate over time (P ¼ 0.14, two sided) and just a slight increase in absolute numbers of autologous HSCT (P ¼ 0.22, two sided), with just a slight increase in its growth rate (P ¼ 0.45, two sided). Countries in the middleincome category also showed a clear increase in absolute numbers of allogeneic HSCT (Po0.01, two sided), with a slight decrease in its growth rate over time (P ¼ 0.26, two sided), but as well as a clear increase in absolute numbers of autologous HSCT (Po0.01, two sided), with just a slight decrease in its growth rate (P ¼ 0.30, two sided). Countries in the low-income category showed both a clear expected increase in absolute numbers of allogeneic and autologous HSCT (P ¼ 0.01 allogeneic, Po0.01 autologous, two sided), with a slight decrease in growth rates (P ¼ 0.50 allogeneic, P ¼ 0.81 autologous, two sided).
EBMT practice guidelines appeared to have an impact (Figures 5c and d) . There was a clear increase in absolute numbers of allogeneic and autologous HSCT within the categories 'standard' and 'clinical option' (Po0.01, both autologous and allogeneic, two sided), with a slight decrease (P ¼ 0.12 allogeneic, two sided) or increase (P ¼ 0.55 autologous, two sided) in the growth rate over time.
In contrast, there was just a slight increase in absolute numbers of allogeneic HSCT within the categories 'developmental' and 'generally not recommended' (P ¼ 0.47, two sided), with just a slight increase in growth rate (P ¼ 0.50, two sided). For autologous HSCT, there was a clear decrease in absolute numbers for the categories 'developmental' and 'generally not recommended' (Po0.01, two sided).
Discussion
Data from this report describe the current state of art of HSCT in Europe in 2009. They document and confirm the ongoing role of autologous and allogeneic HSCT for a broad range of malignant and non-malignant disorders. 3 Data show clearly that allogeneic HSCT is the preferred procedure for patients with leukemias and non-malignant disorders, and autologous HSCT the preferred procedure for patients with lymphoproliferative disorders and some solid tumors. In addition, they show some novel and interesting trends. This 2009 survey confirms the previous trends concerning stem cell source and donor type for allogeneic HSCT. 6, 10 Peripheral blood is the stem cell source of choice in autologous HSCT and is the preferred source in allogeneic HSCT for malignant disorders. BM is the preferred stem cell source in allogeneic HSCT for non-malignant disorders. Here, data from other studies show a clear advantage in overall survival of BM as stem cell source; it should be declared as the preferred choice. [15] [16] [17] The survey confirms as well the increasing role of unrelated donors in allogeneic HSCT with more unrelated than HLA-identical sibling donors. 6 The survey fits into the previously documented trend of a high predictability of HSCT rates and of an absence of plateau, 9 with some exceptions. Numbers of allogeneic HSCT increased over the last 5 years by about 50% and numbers of autologous HSCT by about 12%. Numbers increased most in absolute terms for AML, the most frequent indication for an allogeneic HSCT today, an indication where multiple prospective and retrospective studies indicate an advantage of allogeneic HSCT compared with a non-transplant strategy, and their outcome has substantially improved over the past years. [18] [19] [20] [21] Increase in relative terms was highest for patients with lymphoproliferative disorders, multiple myeloma, CLL and myelodysplastic syndrome.
As such, the data from the survey indicate key fields for further investigations. There is an urgent need to provide evidence in addition to expectation and to define the role of allogeneic HSCT in these disorders by prospective controlled studies. 11, 22 The same considerations apply to the role of autologous HSCT for patients with leukemia, where 
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The survey confirmed the role of reduced-intensity conditioning for allogeneic HSCT, with a constant proportion of reduced-intensity conditioning of about 40%. It is interesting to note that the numbers of patients treated for the first time with donor lymphocyte infusions corresponds equally to about 40% of all allogeneic HSCT. It cannot be documented by the survey, but deduced that the vast majority of patients treated with reduced-intensity conditioning will receive donor lymphocyte infusions over time.
Several years ago, the survey showed clearly the marked difference in transplants and transplant growth rates depending on the economic status of the participating countries as defined by their World Bank Category. 8 Countries with high income performed more transplants and presented higher growth rates than countries with middle or low income. We were specifically interested to know whether there were signs for a plateau in transplant growth rates and whether the increase in absolute transplant numbers was owing more to catching up by less rich countries. The detailed analysis gave clear but different results for allogeneic and autologous HSCT. Allogeneic HSCT continues to increase in all World Bank categories, but with a trend for a decreasing growth rate in high-and middle-income countries. In contrast, autologous HSCT numbers are stable in high-income countries, with still an increase and decrease in growth rate in middle-and low-income countries.
In this context, it is specifically interesting to note that autologous HSCT declined for those indications considered by the EBMT practice guidelines as developmental or generally not recommended, but continued to increase, in all categories, for the indications considered as standard or optional.
14 The same holds true in principle for allogeneic HSCT with the exception of a slow, and in absolute numbers low, increase in HSCT for developmental or not recommended indications. Apparently, more research is performed to test new indications with allogeneic HSCT than autologous HSCT. It is also comforting to see that centers adhere to the EBMT practice guidelines.
In summary, the 2009 activity survey data of the EBMT describe status of HSCT in Europe. They identify current needs for research and describe trends for the future. As such, they provide a platform for patient and physician counseling and can give guidance for health-care planning.
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